Published in:
01-09-2021 | Umeclidinium | Correction
Correction to: Inhalation Therapy for Stable COPD: 20 Years of GOLD Reports
Published in: Advances in Therapy | Issue 9/2021
Login to get accessExcerpt
In the Original Article, Table 4 was published incorrectly. The correct Table 4 is given below.
Table 4
Drug combinations, devices and doses for treating patients with stable COPD in the GOLD reports, 2001–2020
|
Drug
|
Inhaler (μg)
|
Solution for nebulizer (mg/ml)
|
Duration of action (h)
|
|---|---|---|---|
|
Combination short-acting β2-agonists plus anticholinergic in one inhaler
|
|||
|
Fenoterol/Ipratropiuma
|
200/80 (pMDI)
|
1.25/0.5 in 4 ml
|
6–8
|
|
Albuterol/Ipratropiuma
|
75/15 (pMDI)b
|
0.75/4.5 → 0.5, 2.5 in 3 mlc
|
6–8
|
|
100/20 (SMI)d
|
6–8
|
||
|
Combination long-acting β2-agonists plus anticholinergic in one inhaler
|
|||
|
Indacaterol/glycopyrroniume
|
85/43 (DPI)
|
24
|
|
|
Vilanterol/umeclidiniumf
|
25/62.5 (DPI)
|
24
|
|
|
Formoterol/aclidiniumg
|
12/340 (DPI)
|
12
|
|
|
Olodaterol/tiotropiumh
|
5/5 (SMI)
|
24
|
|
|
Formoterol/glycopyrroniumi
|
9.6/14.4 → 9.6/18 (pMDI)
|
12
|
|
|
Formoterol/glycopyrrolatej
|
4.8/9
|
12
|
|
|
Combination long-acting β2-agonists plus glucocorticosteroids in one inhaler
|
|||
|
Formoterol/Budesonidek
|
4.5/160 (pMDI)
|
||
|
9/320 (DPI)
|
|||
|
Formoterol/mometasonel
|
10/200, 10/400 (pMDI)
|
||
|
Salmeterol/Fluticasonem
|
50/100, 250, 500 (DPI)
|
||
|
25/50, 125, 250 (pMDI)
|
|||
|
Vilanterol/Fluticasone furoaten
|
25/100 (DPI)
|
||
|
Formoterol/Beclomethasoneo
|
6/100 (pMDI & DPI)
|
||
|
Triple Combination in one device (LABA/LAMA/ICS)p
|
|||
|
Fluticasone/umeclidinium/vilanterolq(DPI)
|
|||
|
Beclometasone/formoterol/glycopyrroniumr (pMDI)
|
|||